CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel immune modulatory oligonucleotides (IMO), chemical modifications of IMOs, compositions containing IMOs with other therapeutic agents, and the use of IMOs to therapeutically treat a broad range of diseases.
